

Date: 22<sup>nd</sup> October, 2020

To,  
The Manager,  
Department of Corporate Services,  
BSE Limited  
P. J. Towers, Dalal Street,  
Fort, Mumbai – 400 001

Dear Sir/Madam,

**Sub: Alembic Pharmaceuticals announces its joint venture, Aleor Dermaceuticals Limited, receives USFDA Final Approval for Tavaborole Topical Solution, 5%.**

With reference to the captioned subject, this is to inform the exchange that the Company's joint venture, Aleor Dermaceuticals Limited, has received US Food and Drug Administration (USFDA) Final Approval for Tavaborole Topical Solution, 5%.

Please find enclosed herewith our press release.

We request you to kindly take the same on record.

Thanking you,

Yours faithfully,  
**For Alembic Pharmaceuticals Limited**



**Charandeep Singh Saluja**  
**Company Secretary**

Encl.: A/a.

